Article
Amgen says Lumakras plus immunotherapy for lung cancer needs further study
Rating:
0.0
Views:
42
Likes:
1
Library:
1
A small study of Amgen Inc's Lumakras drug combined with immunotherapy found it helped 29% of advanced lung cancer patients, but liver toxicity was high and further study is needed, the company said ahead of the data presentation on Sunday at the World Conference on Lung Cancer in Vienna.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value